A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
Launched by KYOWA KIRIN CO., LTD. · Apr 5, 2012
Trial Information
Current as of June 06, 2025
Terminated
Keywords
ClinConnect Summary
An exploratory study to investigate the effects of RTA 402 on glomerular filtration rate in CKD patients with type 2 diabetes mellitus.
To evaluate the safety of RTA 402.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CKD patients with type 2 diabetes mellitus
- • Patients whose eGFR levels are eligible for this study
- • Patients being treated with stable dose of ACE inhibitors and/or ARB etc.
- Exclusion Criteria:
- • Patients with Type 1 diabetes
- • Patients with known non-diabetic renal disease
- • Patients with a history of renal transplantation
- • Patients with mean SBP \> 160 mmHg or mean DBP \> 90 mmHg
- • Patients with HbA1C \> 10%
- • Patients with cardiovascular disease specified in the study protocol
- • Patients for whom Inulead® injection is contraindicated etc.
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs. With a strong emphasis on biotechnology, the company focuses on areas such as oncology, nephrology, and immunology, leveraging advanced research and development capabilities to enhance patient outcomes. Kyowa Kirin is committed to ethical practices and collaboration in clinical trials, ensuring the highest standards of safety and efficacy in its therapeutic offerings. Through its dedication to scientific excellence and patient-centric approaches, Kyowa Kirin strives to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Koga City, Ibaraki, Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials